Wolters Kluwer Launches Medi-Span Expert AI As Shares Screen Undervalued

Simply Wall St

Mon, February 16, 2026 at 4:08 PM GMT+9 2 min read

In this article:

WOLTF

+15.13%

WTKWY

+6.14%

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Wolters Kluwer Health (ENXTAM:WKL) has launched Medi-Span Expert AI, a new AI-focused medication intelligence platform.

The product is designed to plug into third-party clinical, patient, and administrative workflows to support healthcare AI applications.

The launch adds an AI-ready layer to Wolters Kluwer Health’s existing drug data and clinical decision support offerings.

For investors looking at ENXTAM:WKL, this move sits squarely in the company’s core healthcare information and software business. Medi-Span Expert AI turns Wolters Kluwer’s medication data assets into a tool that software vendors and providers can use inside their own systems, which may be important as hospitals and health tech firms focus on safer prescribing and automation.

Looking ahead, the key questions are around uptake, how widely third-party platforms adopt Medi-Span Expert AI, and how it fits alongside other Wolters Kluwer Health products. For investors, the product illustrates how the company is positioning itself around AI use cases in clinical workflows rather than building patient-facing apps directly.

Stay updated on the most important news stories for Wolters Kluwer by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Wolters Kluwer.

ENXTAM:WKL Earnings & Revenue Growth as at Feb 2026

We’ve flagged 2 risks for Wolters Kluwer. See which could impact your investment.

Quick Assessment

**✅ Price vs Analyst Target**: At €64.18 versus a €139.18 analyst target, the price sits about 54% below consensus expectations.

**✅ Simply Wall St Valuation**: Simply Wall St estimates the shares are trading 15.1% below fair value, which screens as undervalued.

**❌ Recent Momentum**: The 30 day return of roughly 0.27% decline points to soft recent sentiment despite the AI news.

There is only one way to know the right time to buy, sell or hold Wolters Kluwer: head to Simply Wall St’s company report for the latest analysis of Wolters Kluwer’s Fair Value.

Key Considerations

📊 Medi-Span Expert AI keeps the focus on healthcare software and data, which is already a core part of Wolters Kluwer’s business model.

📊 Watch how quickly healthcare providers and third party platforms plug this into prescribing and clinical decision tools, as that will show how useful the product is.

⚠️ With two identified minor risks around debt levels and dividend stability, investors may want to see how any AI related investment spending influences leverage and payouts over time.

 






Story Continues  

Dig Deeper

For the full picture, including more risks and rewards, check out the complete Wolters Kluwer analysis. Alternatively, you can visit the community page for Wolters Kluwer to see how other investors believe this latest news will impact the company’s narrative.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include WKL.AS.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info